William Blair Has Positive Estimate for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – William Blair raised their Q2 2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a note issued to investors on Wednesday, May 7th. William Blair analyst M. Smock now expects that the medical research company will post earnings per share of $2.49 for the quarter, up from their prior forecast of $2.40. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.52 EPS, FY2025 earnings at $9.79 EPS and FY2026 earnings at $10.83 EPS.

A number of other research analysts have also weighed in on CRL. Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Mizuho decreased their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a report on Wednesday, April 9th. Robert W. Baird raised their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $176.00.

Charles River Laboratories International Trading Up 0.9%

Shares of NYSE:CRL opened at $144.38 on Monday. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $254.15. The firm has a market capitalization of $7.09 billion, a price-to-earnings ratio of 962.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business’s 50 day moving average price is $137.41 and its 200-day moving average price is $165.78.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter last year, the firm posted $2.27 EPS. The business’s revenue was down 2.7% on a year-over-year basis.

Insider Transactions at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

A number of hedge funds and other institutional investors have recently modified their holdings of CRL. Rothschild Investment LLC increased its position in shares of Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $31,000. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Finally, Optiver Holding B.V. acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth about $37,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).